← All trials
NCT06747455
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2025
- Primary completion
- Oct 1, 2028
- Completion date
- Dec 31, 2028
- First posted
- Dec 24, 2024
- Last posted
- Dec 24, 2024
- Enrollment
- 438
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.